0 projects

Date from new to old

EIC-The European Innovation Council (EIC)

NEXT GENERATION IMAGING FOR REAL-TIME DOSE VERIFICATION ENABLING ADAPTIVE PROTON THERAPY

Awarded: NOK 17.8 mill.

Project Period: 2024-2028

Location: Vestland

EIC-The European Innovation Council (EIC)

Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.

Awarded: NOK 25.2 mill.

Project Period: 2024-2028

Location: Oslo

MSCA-Marie Sklodowska-Curie Actions (MSCA)

DSTrain - Data Science Postdoctoral Training Programme

DSTrain is a 5-year postdoctoral programme that will award 36 postdoctoral fellowship positions of 36 months each in two calls over the programme period within the overarching frame of data science. The programme will train researchers and innovators with disciplinary, interdisciplinary and trans...

Awarded: NOK 52.1 mill.

Project Period: 2024-2028

Location: Trøndelag - Trööndelage og 12 andre

CL1-Health

ENTEROVIRUS-LINKED TYPE 1 DIABETES EXPOSED -MECHANISMS AND PREVENTION

Awarded: NOK 7.3 mill.

Project Period: 2024-2027

Location: Oslo

CL1-Health

Multimodal 3D Holographic tool and real-time Guidance System with point-of-care diagnostics for surgical planning and interventions on liver and pancreatic cancers

Perioperative care is an intricate process that encompasses 1) preoperative evaluation, surgical planning and preparation; 2) intraoperative procedure; and 3) postoperative management. Perioperative care depends on clinical decision-making, a continuous process that involves many healthcare profe...

Awarded: NOK 44.6 mill.

Project Period: 2024-2027

Location: Trøndelag - Trööndelage og 2 andre

MSCA-Marie Sklodowska-Curie Actions (MSCA)

Human - Centric Indoor Climate for Healthcare Facilities

Awarded: NOK 9.0 mill.

Project Period: 2024-2027

Location: Trøndelag - Trööndelage

CL1-Health

The first European Digital Health Technology Assessment framework co-created by all stakeholders along the value chain

Awarded: NOK 21.5 mill.

Project Period: 2024-2027

Location: Troms - Romsa - Tromssa og 2 andre

CL1-Health

The malignant Glioma immuno-oncology matchmaker: towards data-driven precision medicine using spatially resolved radio-multiomics

Adult and paediatric malignant glioma (GBM and pHGG) remain among the most difficult-to-treat cancers with 5-year survival rates of <5% despite intensive standard-of-care therapy. The differences among patients and the heterogeneous and plastic nature of each individual tumour have resulted in al...

Awarded: NOK 12.2 mill.

Project Period: 2024-2028

Location: Oslo

CL1-Health

Development of a global diagnostic ecosystem for detecting and monitoring emergency-prone pathogens across species and in a unified way

Awarded: NOK 9.4 mill.

Project Period: 2023-2027

Location: Vestland

CL1-Health

Targeting Epstein-Barr Virus Infection for Treatment and Prevention of Multiple Sclerosis

Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central nervous system (CNS). It constitutes the most common non-traumatic cause of neurological impairment among young and middle-aged people and represents a major healthcare burden. Our recent research strongly i...

Awarded: NOK 29.6 mill.

Project Period: 2023-2028

Location: Rogaland og 5 andre

CL5-Climate, Energy and Mobility

From solar energy to fuel: A holistic artificial photosynthesis platform for the production of viable solar fuels

REFINE develops and demonstrates a system of artificial photosynthesis by combining both dark and light-dependent reactions for the direct production of high energy density and essential chemicals, such as alcohols. To achieve this, a direct hydrogen storage into hydrocarbons through CO2 capture ...

Awarded: NOK 21.8 mill.

Project Period: 2023-2027

Location: Akershus og 2 andre

CL1-Health

PREDICTION OF ALZHEIMER’S DISEASE USING AN AI DRIVEN SCREENING PLATFORM

Alzheimer’s disease (AD) and related disorders leading to dementia are associated with staggering costs and suffering. Recently, there has been some progress in the search for effective therapeutic interventions and it is clear that any treatment is likely to be most effective if administered at ...

Awarded: NOK 11.9 mill.

Project Period: 2023-2027

Location: Rogaland

ERC-European Research Council (ERC)

Targeting Acute Leukemia with TdT-TCR-T-cell therapy

Awarded: NOK 1.7 mill.

Project Period: 2023-2025

Location: Akershus og 2 andre

CL1-Health

PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials

Awarded: NOK 18.2 mill.

Project Period: 2023-2028

Location: Oslo

CL1-Health

Reconstruction and Computational Modelling for Inherited Metabolic Diseases

Our overall objectives are to accelerate the diagnosis, and enable personalised management, of inherited metabolic diseases (IMDs). Established academic technology for statistical genomic analysis, deep learning-based prediction of protein structure, and whole-body metabolic network modelling sha...

Awarded: NOK 0.10 mill.

Project Period: 2023-2027

Location: Oslo

CL1-Health

TOWARDS LARGE-SCALE ADAPTION AND TAILORED IMPLEMENTATION OF EVIDENCE-BASED PRIMARY CANCER PREVENTION PROGRAMMES IN EUROPE AND BEYOND

Awarded: NOK 1.8 mill.

Project Period: 2023-2027

Location: Vestland

CL1-Health

IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs

Current evidence from both randomized trials and real-world evidence studies suggests that older breast cancer patients derive clinical benefit from the addition of CDK 4/6-inhibitors to endocrine therapy but with higher risk for adverse events and treatment discontinuation compared to younger pa...

Awarded: NOK 3.7 mill.

Project Period: 2023-2028

Location: Akershus

CL1-Health

International Study for Treatment of Childhood Relapsed ALL 2020

Relapse of acute lymphoblastic leukemia (ALL) remains a leading cause of mortality in childhood cancer. IntReALL 2020 will conduct randomized and historically controlled trials in children with relapsed B-cell precursor (BCP) ALL with the aim to replace toxic chemotherapy with better tolerated an...

Awarded: NOK 1.1 mill.

Project Period: 2023-2028

Location: Oslo

CL1-Health

COMPREHENSIVE CANCER INFRASTRUCTURES 4 EUROPE

Cancer is the second leading cause of death in Europe with an expected increase of about 25% by 2035. A wide and unacceptable variability in terms of access to research, innovation and quality care exists between and within countries. Possible solutions are an increase in knowledge by funding res...

Awarded: NOK 3.2 mill.

Project Period: 2023-2026

Location: Oslo

MSCA-Marie Sklodowska-Curie Actions (MSCA)

Guiding glioblastoma treatments by decrypting tumor biomechanics via Magnetic Resonance Elastography.

Glioblastoma multiforme (GBM) is the most common and deadly type of primary brain tumour, carrying a dire prognosis with a median survival of 14.6 months for patients undergoing standard treatments. The causes of poor clinical prognosis are late diagnosis, diffuse infiltration, pseudo necrosis, h...

Awarded: NOK 2.9 mill.

Project Period: 2023-2026

Location: Oslo

CL1-Health

Establishing of Cancer Mission Hubs: Networks and Synergies

Cancer- healthcare, research and innovation face core common challenges, such as fragmentation of initiatives and distancing from important stakeholders, requiring coordinated solutions. These challenges are recognized in Horizon Europe’s Cancer Mission Implementation Plan and in Europe’s Beating...

Awarded: NOK 3.7 mill.

Project Period: 2023-2026

Location: Oslo og 3 andre

MSCA-Marie Sklodowska-Curie Actions (MSCA)

Combination therapy for the treatment of metastatic melanoma using magnetic nanoparticles

Metastatic melanoma is a hard-to-treat disease and it remains as one of the most worrisome cancer. There is an urgent need to improve the current therapies (chemotherapy, radiotherapy) that have a limited efficacy. A single therapy is not efficient to tackle metastatic melanoma and a combination ...

Awarded: NOK 3.0 mill.

Project Period: 2023-2027

Location: Oslo

ERC-European Research Council (ERC)

Final act of the autophagy symphony: Whole-organism orchestration of autophagy termination

When an organism experiences physiological stresses, such as nutrient starvation, it activates several mechanisms to promote its survival. One of these mechanisms is autophagy, which is a catabolic pathway conserved from yeast to man that functions as a recycling system during normal physiology, ...

Awarded: NOK 15.2 mill.

Project Period: 2023-2027

Location: Oslo

MSCA-Marie Sklodowska-Curie Actions (MSCA)

Determining Genetic Bases of Differential Response to Antipsychotics Using Patient-Derived Neurons

Schizophrenia (SCZ) affects 20 million people worldwide and antipsychotics remain the only effective pharmacological intervention. However, one-third of people with SCZ do not respond to first-line antipsychotic drugs. In the absence of clinical biomarkers to stratify SCZ subtypes, all individual...

Awarded: NOK 3.1 mill.

Project Period: 2023-2025

Location: Vestland

CL1-Health

CANCER PREVENTION VS CANCER TREATMENT: THE RARE TUMOUR RISK SYNDROMES BATTLE

Awarded: NOK 3.5 mill.

Project Period: 2023-2025

Location: Vestland

CL1-Health

Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe

Awarded: NOK 7.6 mill.

Project Period: 2023-2026

Location: Oslo

WIDENING-Widening participation and spreading excellence

Diabetes, obesity and the Kidney

Chronic kidney disease is a major cause of morbidity and mortality in the EU. About 10-15% of the EU population has chronic kidney disease (CKD) and this number is expected to increase in the future decades. Diabetes is today the main cause of CKD in the EU: about, 30% of the cases with dialysi...

Awarded: NOK 2.9 mill.

Project Period: 2023-2025

Location: Oslo

CL1-Health

Maximising Impact of Prescription Drugs in Rheumatoid Arthritis

The SQUEEZE consortium comprehensively addressed how biomarkers can be used to optimize disease modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis (RA). RA is a chronic immune-mediated disease with enormous health-related quality of life and socioeconomic impact. A broad choice of DM...

Awarded: NOK 21.1 mill.

Project Period: 2022-2027

Location: Oslo

EIC-The European Innovation Council (EIC)

Supervised morphogenesis in gastruloids

The lack of realistic in vitro organ models that can faithfully represent in vivo physiological processes is a major obstacle affecting the biological and medical sciences. The current gold standard is animal experiments, but it is increasingly clear that these models mostly fail to recapitulate ...

Awarded: NOK 13.6 mill.

Project Period: 2022-2027

Location: Oslo

CL1-Health

Fostering a European Research Area for Health Research

Excellent EU programs push health R&I but are not sufficient. Synergy with strategic initiatives in MS and a new model for impactful collaborations are needed to address the challenges for health. ERA4Health brings the opportunity to increase EU transnational collaborative research funding by cre...

Awarded: NOK 15.8 mill.

Project Period: 2022-2029

Location: Vestland og 2 andre

1 2 3 4 5